Canine Parvovirus Monoclonal Antibody is the first and only USDA-conditionally approved monoclonal antibody (mAb) treatment that targets canine parvovirus (CPV).

2023年5月2日 · With an estimated 330,000 cases of canine parvovirus available for treatment in the U.S. annually 2, clinical trials demonstrate that the Canine Parvovirus Monoclonal Antibody single, intravenous dose delivers targeted efficacy in treating this deadly disease.

Canine Parvovirus Monoclonal Antibody is the first and only USDA-conditionally approved monoclonal antibody (mAb) treatment that targets CPV. Now you can take charge of parvo with a targeted treatment that helps ease the stress of your patients, your clients and your clinic. Targets parvovirus directly Single-dose efficacy High safety profile

2024年4月2日 · Canine Parvovirus Monoclonal Antibody (CPMA) is the first USDA-conditionally approved, one-dose treatment option for parvovirus in dogs 8 weeks of age and older. CPMA is a synthetic antibody that mimics a dog’s own antibodies, binding to canine parvovirus and neutralizing it before it can enter the cell, delivering a high level of defense (2).

2023, Canine Parvovirus Monoclonal Antibody (CPMA) is the first and only USDA conditionally approved targeted parvovirus treatment, bringing with it the potential to change outcomes for individual patients, pet owners, veterinary teams, and shelter communities. Dr. Miller: Since the onset of canine parvovirus in the 1970s, we’ve made great

GREENFIELD, Ind (October 15, 2024) – Elanco Animal Health today unleashed the first ever real-world data demonstrating the efficacy and impact of its Canine Parvovirus Monoclonal Antibody (CPMA), the first and only USDA Conditionally Approved targeted treatment for canine parvovirus.

2023年5月10日 · Canine Parvovirus Monoclonal Antibody—Elanco's first monoclonal antibody treatment—is a single, intravenous dose used to treat clinical signs caused by parvo in sick puppies and dogs, regardless of vaccination status.

Canine Parvovirus Monoclonal Antibody (CPMA) is the first and only USDA-conditionally approved, one-dose parvovirus treatment. Think your dog might have parvovirus? Treatment can’t wait. Canine parvovirus is a highly contagious disease that destroys the intestinal lining. It can be fatal if not treated quickly.

Like a dog’s own antibodies, CPMA is a synthetic antibody that binds to canine parvovirus. When CPMA binds, it neutralizes parvovirus before the virus can enter the cell. 1,2 CPMA essentially delivers an immediate high level of defense against parvovirus.

The product, Canine Parvovirus Monoclonal Antibody, selectively binds and neutralizes canine parvovirus. This product is a sterile liquid containing a chimeric monoclonal antibody (rat variable region, canine constant region) against canine parvovirus (CPV) viral protein 2.